Problems in identifying functional erythropoietin receptors in cancer tissue [1]

Journal of Clinical Oncology

Volumn 25, Issue 12, 2007, Pages 1627-1628

  Jelkmann, Wolfgang ^a   Laugsch, Magdalena ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; HEAT SHOCK PROTEIN 70; RECOMBINANT ERYTHROPOIETIN; SMALL INTERFERING RNA; ERYTHROPOIETIN; TUMOR MARKER;

ANEMIA; ANTIBODY SPECIFICITY; ANTIGEN BINDING; CANCER CELL CULTURE; CANCER TISSUE; CELL GROWTH; CELL PROLIFERATION; CROSS REACTION; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYPOPHARYNX TUMOR; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LETTER; METHODOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; WESTERN BLOTTING; CELL CULTURE; DISEASE COURSE; DRUG EFFECT; GENETICS; HEAD AND NECK TUMOR; METABOLISM; NEEDLE BIOPSY; NEOVASCULARIZATION (PATHOLOGY); NOTE; PATHOLOGY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

BIOPSY, NEEDLE; DISEASE PROGRESSION; ERYTHROPOIETIN; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, ERYTHROPOIETIN; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 34248159386     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.9728     Document Type: Letter

References (13)

1. Henke M, Mattern D, Pepe M, et al: Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24:4708-4713, 2006
2. Acs G, Acs P, Beckwith SM, et al: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561-3565, 2001
3. Westphal G, Niederberger E, Blum C, et al: Erythropoietin and G-CSF receptors in human tumor cells: Expression and aspects regarding functionality. Tumori 88:150-159, 2002
4. Elliott S, Busse L, Bass MB, et al: Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107:1892-1895, 2006
5. Laugsch M, Metzen E, Jelkmann W: Evidence against effects of erythropoietin on tumor cells. Ann Hematol 85:660, 2006 (abstr 58)
6. Sinclair A, Busse L, Rogers N, et al: EPO receptor transcription is not elevated nor predictive of surface expression in human tumor cells. Proc Amer Assoc Cancer Res 46:5457, 2005 (abstr)
7. Abdalla A, Kokhaei P, Lotta Hansson L, et al: Expression of erythropoietin receptor (EPO-R) and in vitro functional effects of epoetin in B-cell malignancies. Blood 106:4278, 2005 (abstr)
8. Wollman Y, Westphal G, Blum M, et al: The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line. Life Sci 59:315-322, 1996
9. Batra S, Perelman N, Luck LR, et al: Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477-1487, 2003
10. Cheung W, Minton N, Gunawardena K: Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 57:411-418, 2001
11. Henke M, Laszig R, Rübe C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260, 2003
12. Glaspy J, Dunst J: Can erythropoietin therapy improve survival? Oncology 67:5-11, 2004 (suppl 1)
13. Bokemeyer C, Aapro MS, Courdi A, et al: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258-270, 2007